OR WAIT null SECS
A patient’s near-fatal journey from undiagnosed fatty liver disease to liver transplant highlights the urgent need for better screening and stigma-free communication.
Fatty liver disease is a growing public health crisis — yet it often remains undetected until catastrophic events force a diagnosis. Jerry Rosenberg’s story is a powerful reminder of this reality and offers key takeaways for physicians working at the intersection of primary care, hepatology, critical care, and transplant medicine.
Without traditional risk factors or a known diagnosis, Rosenberg went from a healthy, active lifestyle to a coma and liver failure within days — his first real sign that something was wrong.
Before his health crisis, Rosenberg was thriving. He co-owned a nightclub, exercised regularly, maintained a healthy weight, and traveled extensively. Despite his active lifestyle and lack of alcohol consumption, he unknowingly had advanced fatty liver disease.
“I had just received a clean bill of health from my doctor,” Rosenberg said. “I didn’t drink. Liver disease wasn’t something I was ever told to worry about.”
The turning point came while on vacation, after a suspected case of food poisoning. Within days, Rosenberg collapsed and entered hepatic coma. Local doctors in Bermuda offered little hope of survival. Only after multiple international care coordination efforts was he airlifted to Florida, and later accepted into Mayo Clinic’s transplant program.
Rosenberg’s experience reflects a broader pattern seen across healthcare settings. Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), now affect at least 30% of Americans, yet diagnosis rates remain low.
Multiple studies show that NAFLD often goes undetected in primary care, even when patients have risk factors like obesity, diabetes, or metabolic syndrome. However, Rosenberg didn’t fit even those profiles — further underscoring the need for more nuanced risk assessment and screening tools beyond conventional assumptions.
Rosenberg’s journey also highlights challenges in transplant triage, especially for patients presenting with acute liver failure without a clear etiology.
With few hospitals willing to accept him, Rosenberg’s case required rapid, cross-border coordination between emergency medical teams, hepatologists, transplant centers, and intensive care specialists.
Post-transplant, his rehabilitation was extensive. Prolonged ICU stays led to muscle atrophy, requiring inpatient rehab and nursing home care to regain basic mobility.
“Learning to walk again was one of the hardest parts,” Rosenberg recalled. “My brother, who was also my caregiver, pushed me every day.”
Despite his medical history, Rosenberg frequently encountered stigma—both in the hospital and in his community.
“There was an automatic assumption that my liver failure was alcohol-related,” he said. “That stigma was hurtful and it’s still something I speak out about.”
For clinicians, this highlights an important care gap: Addressing biases and misconceptions when communicating with patients about liver disease. Not all patients with liver failure have a history of alcohol misuse. This is especially true as NAFLD/NASH continues to rise as a leading cause of transplantation.
Today, Rosenberg is a vocal advocate with the Global Liver Institute (GLI). He speaks at medical schools, health fairs, and policy events to raise awareness about fatty liver disease and the need for increased organ donation.
He urges physicians to:
“I want doctors to know that their words matter,” Rosenberg said. “You could catch this early for someone else.”
As Rosenberg’s story makes clear, liver disease is not always visible — but its consequences can be life-altering.